2Kereiakes D J, Fry E, Matthai W,et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention:" NICE guys finish first. " [ J ]. J Invasive Cardiol, 2000,12 ( Suppil A ): 1A-5A.
3Kereiakes D J, Grines C, Fry E, et al. Enoxaparin and abciximab,adjunctive pharmacotherapy during percutaneous coronary intervention [J]. J Invasive Cardiol.2001.13 :272-278.
5Rosborough K T. Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time [ J ]. ,1999,19 (6) :761-766.
二级参考文献15
1Manson L, Weitz IJ, Podor JT,et al. The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. J Lab Clin Med, 1997, 130(6):649-655.
2Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest, 2001, 119: 176-193.
3Brown G, Dodek P. An evaluation of empiric vs.nomogram-based dosing of haparin in an intensive care unit. Crit Care Med, 1997, 25(9):1534-1538.
4Geogory MS. Weight-based heparin dosing: Maybe it is just a matter of time . Crit Care Med ,1997, 25(9):1451-1452.
5Rosborough KT. Monitoring unfractionated heparin therapy with antifactor Ⅹa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time. Pharmacoeconomics ,1999,19(6):761-766.
6Hirsh J, Warkentin ET, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmcokinetics, dosing considerations, monitoring, efficacy, and safety. Chest, 1998 ,114(5): 489-503.
7Kitchen S, Preston FE. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thrombosis and Haemostasis, 1996,75(5):734-739.
8Kearon C, Johnson M, Moffat K, et al. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med, 1998, 158(25):1140-1143.
9Smythe AM, Koerber MJ, Westley JS, et al. Different Heparin Lots--Does It Matter? Arch Pathol Lab Med, 2001, 125:1458-1462.
10Granger BC, Hirsh J, Califf MR, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: result from the GUSTO-1 trail. Circulation,1996,93 (5):870-877.
